Obermatt
See Similar Stocks →

Opus Genetics

NAQ:IRD · US67577R1023
BiotechnologySmall

360° View

52
Price/Sales16
Price/Earnings70
Price/Book77
Dividend Yield1
Revenue Growth49
Profit Growth37
Capital Growth25
TSR 52w100
Leverage75
Liquidity12
Refinancing41
Combined39
Analyst Opinions80
Pro Holdings45
Opinion Changes81
Market Pulse11

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees31
Websiteopusgtx.com
ISINUS67577R1023
Last UpdateApr 2, 2026
Index & Theme
DiabetesOphthalmologyGenetic DisorderGeneticsBiopharmaBiotechnologyPharmaceutical

Description

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is focused on developing gene therapies for the treatment of inherited retinal diseases (IRDs), as well as other therapies for additional ophthalmic disorders. Pipeline The…

Analysis

Opus Genetics's 360° View rank of 52 places it above its peer average — better than 52% of its true peers.

It's growing solidly (56) and reasonably valued (52). On safety it is carrying more balance-sheet risk (36), and the market shows favorable sentiment (65). Taken together, its Combined rank of 39 reads as below its peer average.

360° rank · history

1007550250
52
2026

All-time high

62

Mar 2026

All-time low

52

Jun 2026

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
16
—
—
—
Price/Earnings
70
—
—
—
Price/Book
77
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
52
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Opus Genetics with its peers
Rigel Pharmaceuticals
NSQ:RIGL
66
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →